View Future GrowthHRS 過去の業績過去 基準チェック /16HRSの収益は年間平均-3.2%の割合で減少していますが、 Chemicals業界の収益は年間 増加しています。収益は年間1.3% 0.4%割合で 減少しています。 HRSの自己資本利益率は10.3%であり、純利益率は16.4%です。主要情報-3.23%収益成長率-3.25%EPS成長率Chemicals 業界の成長13.95%収益成長率-0.37%株主資本利益率10.26%ネット・マージン16.44%前回の決算情報31 Mar 2026最近の業績更新分析記事 • May 21Weak Statutory Earnings May Not Tell The Whole Story For HRS (KOSDAQ:036640)HRS Co., Ltd's ( KOSDAQ:036640 ) recent weak earnings report didn't cause a big stock movement. However, we believe...Reported Earnings • Mar 20Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩846 (down from ₩945 in FY 2024). Revenue: ₩78.9b (down 1.7% from FY 2024). Net income: ₩13.5b (down 11% from FY 2024). Profit margin: 17% (down from 19% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.2%. Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.分析記事 • Nov 19HRS' (KOSDAQ:036640) Shareholders May Want To Dig Deeper Than Statutory ProfitHRS Co., Ltd's ( KOSDAQ:036640 ) healthy profit numbers didn't contain any surprises for investors. However the...Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: ₩233 (vs ₩194 in 3Q 2024)Third quarter 2025 results: EPS: ₩233 (up from ₩194 in 3Q 2024). Revenue: ₩20.8b (up 10.0% from 3Q 2024). Net income: ₩3.72b (up 20% from 3Q 2024). Profit margin: 18% (up from 16% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: ₩239 (vs ₩239 in 2Q 2024)Second quarter 2025 results: EPS: ₩239 (in line with 2Q 2024). Revenue: ₩20.3b (down 6.3% from 2Q 2024). Net income: ₩3.81b (flat on 2Q 2024). Profit margin: 19% (up from 18% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.分析記事 • May 20HRS' (KOSDAQ:036640) Solid Earnings May Rest On Weak FoundationsHRS Co., Ltd's ( KOSDAQ:036640 ) healthy profit numbers didn't contain any surprises for investors. We think this is...すべての更新を表示Recent updates分析記事 • May 21Weak Statutory Earnings May Not Tell The Whole Story For HRS (KOSDAQ:036640)HRS Co., Ltd's ( KOSDAQ:036640 ) recent weak earnings report didn't cause a big stock movement. However, we believe...Reported Earnings • Mar 20Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩846 (down from ₩945 in FY 2024). Revenue: ₩78.9b (down 1.7% from FY 2024). Net income: ₩13.5b (down 11% from FY 2024). Profit margin: 17% (down from 19% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.2%. Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Feb 27HRS Co., Ltd, Annual General Meeting, Mar 26, 2026HRS Co., Ltd, Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 7, chupalsandan 2-gil, paengseong-eup, gyeonggi-do, pyeongtaek South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 09 April 2026. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 7.2%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.3%).分析記事 • Nov 19HRS' (KOSDAQ:036640) Shareholders May Want To Dig Deeper Than Statutory ProfitHRS Co., Ltd's ( KOSDAQ:036640 ) healthy profit numbers didn't contain any surprises for investors. However the...Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: ₩233 (vs ₩194 in 3Q 2024)Third quarter 2025 results: EPS: ₩233 (up from ₩194 in 3Q 2024). Revenue: ₩20.8b (up 10.0% from 3Q 2024). Net income: ₩3.72b (up 20% from 3Q 2024). Profit margin: 18% (up from 16% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Declared Dividend • Nov 13First half dividend of ₩300 announcedShareholders will receive a dividend of ₩300. Ex-date: 29th December 2025 Payment date: 9th April 2026 Dividend yield will be 7.5%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (44% earnings payout ratio) and cash flows (51% cash payout ratio). The dividend has increased by an average of 54% per year over the past 6 years. However, payments have been volatile during that time. Earnings per share has grown by 25% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Upcoming Dividend • Sep 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 September 2025. Payment date: 05 November 2025. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 7.4%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.4%).Declared Dividend • Aug 18First half dividend of ₩100.00 announcedShareholders will receive a dividend of ₩100.00. Ex-date: 29th September 2025 Payment date: 5th November 2025 Dividend yield will be 7.4%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (44% earnings payout ratio) and cash flows (51% cash payout ratio). The dividend has increased by an average of 54% per year over the past 6 years. However, payments have been volatile during that time. Earnings per share has grown by 25% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: ₩239 (vs ₩239 in 2Q 2024)Second quarter 2025 results: EPS: ₩239 (in line with 2Q 2024). Revenue: ₩20.3b (down 6.3% from 2Q 2024). Net income: ₩3.81b (flat on 2Q 2024). Profit margin: 19% (up from 18% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.分析記事 • May 20HRS' (KOSDAQ:036640) Solid Earnings May Rest On Weak FoundationsHRS Co., Ltd's ( KOSDAQ:036640 ) healthy profit numbers didn't contain any surprises for investors. We think this is...Reported Earnings • Mar 15Full year 2024 earnings released: EPS: ₩945 (vs ₩758 in FY 2023)Full year 2024 results: EPS: ₩945 (up from ₩758 in FY 2023). Revenue: ₩80.2b (up 2.6% from FY 2023). Net income: ₩15.1b (up 25% from FY 2023). Profit margin: 19% (up from 16% in FY 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 25HRS Co., Ltd, Annual General Meeting, Mar 26, 2025HRS Co., Ltd, Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 7, chupalsandan 2-gil, paengseong-eup, gyeonggi-do, pyeongtaek South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 09 April 2025. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 4.3%. Within top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (2.2%).分析記事 • Dec 06We Like These Underlying Return On Capital Trends At HRS (KOSDAQ:036640)What are the early trends we should look for to identify a stock that could multiply in value over the long term...Declared Dividend • Nov 16Dividend of ₩200 announcedShareholders will receive a dividend of ₩200. Ex-date: 27th December 2024 Payment date: 9th April 2025 Dividend yield will be 6.2%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (40% cash payout ratio). The dividend has increased by an average of 46% per year over the past 5 years. However, payments have been volatile during that time. EPS is expected to grow by 8.8% over the next 2 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Nov 14Third quarter 2024 earnings released: EPS: ₩194 (vs ₩183 in 3Q 2023)Third quarter 2024 results: EPS: ₩194 (up from ₩183 in 3Q 2023). Revenue: ₩18.9b (down 4.7% from 3Q 2023). Net income: ₩3.10b (up 6.0% from 3Q 2023). Profit margin: 16% (up from 15% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 16% per year.New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩87.7b market cap, or US$66.7m).Reported Earnings • May 18First quarter 2024 earnings released: EPS: ₩243 (vs ₩154 in 1Q 2023)First quarter 2024 results: EPS: ₩243 (up from ₩154 in 1Q 2023). Revenue: ₩20.5b (up 7.4% from 1Q 2023). Net income: ₩3.88b (up 58% from 1Q 2023). Profit margin: 19% (up from 13% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Reported Earnings • Mar 12Full year 2023 earnings released: EPS: ₩758 (vs ₩628 in FY 2022)Full year 2023 results: EPS: ₩758 (up from ₩628 in FY 2022). Revenue: ₩78.2b (down 9.2% from FY 2022). Net income: ₩12.1b (up 21% from FY 2022). Profit margin: 16% (up from 12% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Dec 20Upcoming dividend of ₩200 per share at 3.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 3.7%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.8%).Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩183 (vs ₩121 in 3Q 2022)Third quarter 2023 results: EPS: ₩183 (up from ₩121 in 3Q 2022). Revenue: ₩19.8b (down 2.5% from 3Q 2022). Net income: ₩2.93b (up 51% from 3Q 2022). Profit margin: 15% (up from 9.5% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Apr 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩5,850, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 169% over the past three years.Reported Earnings • Mar 12Full year 2022 earnings released: EPS: ₩628 (vs ₩1,303 in FY 2021)Full year 2022 results: EPS: ₩628 (down from ₩1,303 in FY 2021). Revenue: ₩86.1b (up 2.4% from FY 2021). Net income: ₩10.0b (down 52% from FY 2021). Profit margin: 12% (down from 25% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 42% per year whereas the company’s share price has increased by 44% per year.Upcoming Dividend • Dec 21Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 3.5%. Within top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (2.4%).Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩6,240, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 151% over the past three years.Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩6,230, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 140% over the past three years.Reported Earnings • Mar 11Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: ₩1,303 (up from ₩571 in FY 2020). Revenue: ₩84.1b (up 25% from FY 2020). Net income: ₩20.8b (up 126% from FY 2020). Profit margin: 25% (up from 14% in FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Over the next year, revenue is forecast to grow 19%, compared to a 22% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩7,530, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 152% over the past three years.Upcoming Dividend • Dec 22Upcoming dividend of ₩150 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 13% but the company is not cash flow positive. Trailing yield: 2.1%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (1.5%).Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩6,660, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 137% over the past three years.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩191 (vs ₩164 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ₩21.0b (up 23% from 3Q 2020). Net income: ₩3.05b (up 16% from 3Q 2020). Profit margin: 14% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₩9,160, the stock trades at a trailing P/E ratio of 8.2x. Average trailing P/E is 20x in the Chemicals industry in South Korea. Total returns to shareholders of 213% over the past three years.Valuation Update With 7 Day Price Move • Sep 06Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₩6,800, the stock trades at a trailing P/E ratio of 6.1x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 103% over the past three years.Valuation Update With 7 Day Price Move • Jun 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩6,470, the stock trades at a trailing P/E ratio of 10.2x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 55% over the past three years.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩6,040, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 46% over the past three years.分析記事 • Mar 16HRS Co., Ltd's (KOSDAQ:036640) 2.6% Dividend Yield Looks Pretty InterestingCould HRS Co., Ltd ( KOSDAQ:036640 ) be an attractive dividend share to own for the long haul? Investors are often...Reported Earnings • Mar 10Full year 2020 earnings released: EPS ₩571 (vs ₩60.00 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩67.4b (up 1.0% from FY 2019). Net income: ₩9.21b (up ₩8.23b from FY 2019). Profit margin: 14% (up from 1.5% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 01Will HRS' (KOSDAQ:036640) Growth In ROCE Persist?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩5,810, the stock is trading at a trailing P/E ratio of 13.6x, down from the previous P/E ratio of 16.5x. This compares to an average P/E of 17x in the Chemicals industry in South Korea. Total returns to shareholders over the past three years are 30%.Is New 90 Day High Low • Feb 15New 90-day high: ₩7,140The company is up 72% from its price of ₩4,145 on 17 November 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.分析記事 • Feb 11A Look At The Intrinsic Value Of HRS Co., Ltd (KOSDAQ:036640)How far off is HRS Co., Ltd ( KOSDAQ:036640 ) from its intrinsic value? Using the most recent financial data, we'll...Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₩6,730, the stock is trading at a trailing P/E ratio of 15.7x, up from the previous P/E ratio of 12.6x. This compares to an average P/E of 18x in the Chemicals industry in South Korea. Total returns to shareholders over the past three years are 48%.Is New 90 Day High Low • Jan 25New 90-day high: ₩5,750The company is up 67% from its price of ₩3,445 on 27 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 40% over the same period.分析記事 • Jan 24HRS Co., Ltd (KOSDAQ:036640) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?HRS (KOSDAQ:036640) has had a great run on the share market with its stock up by a significant 58% over the last three...Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩5,500, the stock is trading at a trailing P/E ratio of 12.8x, up from the previous P/E ratio of 11.1x. This compares to an average P/E of 15x in the Chemicals industry in South Korea. Total returns to shareholders over the past three years are 31%.Is New 90 Day High Low • Dec 29New 90-day high: ₩5,500The company is up 59% from its price of ₩3,470 on 29 September 2020. The South Korean market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period.分析記事 • Dec 28Did You Miss HRS' (KOSDAQ:036640) 82% Share Price Gain?Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than...Is New 90 Day High Low • Dec 10New 90-day high: ₩4,445The company is up 17% from its price of ₩3,800 on 11 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period.分析記事 • Dec 02These 4 Measures Indicate That HRS (KOSDAQ:036640) Is Using Debt SafelyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Nov 18Third quarter 2020 earnings released: EPS ₩164The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ₩17.2b (up 1.1% from 3Q 2019). Net income: ₩2.63b (up 437% from 3Q 2019). Profit margin: 15% (up from 2.9% in 3Q 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Nov 09New 90-day high: ₩4,080The company is up 24% from its price of ₩3,300 on 11 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period.Is New 90 Day High Low • Oct 12New 90-day high: ₩3,970The company is up 16% from its price of ₩3,435 on 14 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 30% over the same period.収支内訳HRS の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A036640 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 2680,95413,30810,02443931 Dec 2578,91013,5269,78446030 Sep 2579,13015,0519,37344930 Jun 2577,23214,4359,41055731 Mar 2578,59314,4469,46758931 Dec 2480,23415,1109,20664930 Sep 2480,35414,5088,7941,01130 Jun 2481,28414,3328,42197931 Mar 2479,58613,5357,9031,02831 Dec 2378,16912,1077,6561,00230 Sep 2378,66110,7587,47177630 Jun 2379,1629,7697,39477331 Mar 2381,6729,4607,20889831 Dec 2286,09610,0337,1661,00130 Sep 2291,97313,3907,09789930 Jun 2292,69814,5056,80185431 Mar 2289,69921,1237,02066831 Dec 2184,06120,8216,82149030 Sep 2177,36918,2956,66154730 Jun 2173,49917,8746,50961831 Mar 2168,70310,2016,27870031 Dec 2067,4059,2116,34479330 Sep 2065,9126,9556,38368330 Jun 2065,7324,8136,46856331 Mar 2067,3193,0946,55053631 Dec 1966,7209836,60049630 Sep 1968,071-10,3747,19049630 Jun 1969,845-10,3497,85042831 Mar 1973,313-9,1958,15838631 Dec 1874,618-7,4828,17939030 Sep 1873,6384,0597,72529730 Jun 1870,8294,7817,27727631 Mar 1868,2595,6907,04719831 Dec 1767,7206,2887,01112630 Sep 1765,2106,6956,8709830 Jun 1762,6786,0066,8969531 Mar 1759,6965,0076,74613431 Dec 1656,4913,9706,75613430 Sep 1655,8393,3797,28517130 Jun 1656,2963,6977,28228931 Mar 1657,1973,4487,32926031 Dec 1559,7274,1737,33535030 Sep 1559,4634,7906,10773030 Jun 1558,8474,6846,250592質の高い収益: A036640は 高品質の収益 を持っています。利益率の向上: A036640の現在の純利益率 (16.4%)は、昨年(18.4%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A036640の収益は過去 5 年間で年間3.2%減少しました。成長の加速: A036640は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: A036640は過去 1 年間で収益成長率がマイナス ( -7.9% ) となったため、 Chemicals業界平均 ( -3.5% ) と比較することが困難です。株主資本利益率高いROE: A036640の 自己資本利益率 ( 10.3% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 19:50終値2026/05/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HRS Co., Ltd 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Dongwon KimKB Securities Co., Ltd.Hong-Sik JeongLS Securities Co., Ltd.Eui-Seob ShimNH Investment & Securities Co., Ltd.1 その他のアナリストを表示
分析記事 • May 21Weak Statutory Earnings May Not Tell The Whole Story For HRS (KOSDAQ:036640)HRS Co., Ltd's ( KOSDAQ:036640 ) recent weak earnings report didn't cause a big stock movement. However, we believe...
Reported Earnings • Mar 20Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩846 (down from ₩945 in FY 2024). Revenue: ₩78.9b (down 1.7% from FY 2024). Net income: ₩13.5b (down 11% from FY 2024). Profit margin: 17% (down from 19% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.2%. Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
分析記事 • Nov 19HRS' (KOSDAQ:036640) Shareholders May Want To Dig Deeper Than Statutory ProfitHRS Co., Ltd's ( KOSDAQ:036640 ) healthy profit numbers didn't contain any surprises for investors. However the...
Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: ₩233 (vs ₩194 in 3Q 2024)Third quarter 2025 results: EPS: ₩233 (up from ₩194 in 3Q 2024). Revenue: ₩20.8b (up 10.0% from 3Q 2024). Net income: ₩3.72b (up 20% from 3Q 2024). Profit margin: 18% (up from 16% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: ₩239 (vs ₩239 in 2Q 2024)Second quarter 2025 results: EPS: ₩239 (in line with 2Q 2024). Revenue: ₩20.3b (down 6.3% from 2Q 2024). Net income: ₩3.81b (flat on 2Q 2024). Profit margin: 19% (up from 18% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
分析記事 • May 20HRS' (KOSDAQ:036640) Solid Earnings May Rest On Weak FoundationsHRS Co., Ltd's ( KOSDAQ:036640 ) healthy profit numbers didn't contain any surprises for investors. We think this is...
分析記事 • May 21Weak Statutory Earnings May Not Tell The Whole Story For HRS (KOSDAQ:036640)HRS Co., Ltd's ( KOSDAQ:036640 ) recent weak earnings report didn't cause a big stock movement. However, we believe...
Reported Earnings • Mar 20Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩846 (down from ₩945 in FY 2024). Revenue: ₩78.9b (down 1.7% from FY 2024). Net income: ₩13.5b (down 11% from FY 2024). Profit margin: 17% (down from 19% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.2%. Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Feb 27HRS Co., Ltd, Annual General Meeting, Mar 26, 2026HRS Co., Ltd, Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 7, chupalsandan 2-gil, paengseong-eup, gyeonggi-do, pyeongtaek South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 09 April 2026. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 7.2%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.3%).
分析記事 • Nov 19HRS' (KOSDAQ:036640) Shareholders May Want To Dig Deeper Than Statutory ProfitHRS Co., Ltd's ( KOSDAQ:036640 ) healthy profit numbers didn't contain any surprises for investors. However the...
Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: ₩233 (vs ₩194 in 3Q 2024)Third quarter 2025 results: EPS: ₩233 (up from ₩194 in 3Q 2024). Revenue: ₩20.8b (up 10.0% from 3Q 2024). Net income: ₩3.72b (up 20% from 3Q 2024). Profit margin: 18% (up from 16% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Declared Dividend • Nov 13First half dividend of ₩300 announcedShareholders will receive a dividend of ₩300. Ex-date: 29th December 2025 Payment date: 9th April 2026 Dividend yield will be 7.5%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (44% earnings payout ratio) and cash flows (51% cash payout ratio). The dividend has increased by an average of 54% per year over the past 6 years. However, payments have been volatile during that time. Earnings per share has grown by 25% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Upcoming Dividend • Sep 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 September 2025. Payment date: 05 November 2025. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 7.4%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.4%).
Declared Dividend • Aug 18First half dividend of ₩100.00 announcedShareholders will receive a dividend of ₩100.00. Ex-date: 29th September 2025 Payment date: 5th November 2025 Dividend yield will be 7.4%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (44% earnings payout ratio) and cash flows (51% cash payout ratio). The dividend has increased by an average of 54% per year over the past 6 years. However, payments have been volatile during that time. Earnings per share has grown by 25% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: ₩239 (vs ₩239 in 2Q 2024)Second quarter 2025 results: EPS: ₩239 (in line with 2Q 2024). Revenue: ₩20.3b (down 6.3% from 2Q 2024). Net income: ₩3.81b (flat on 2Q 2024). Profit margin: 19% (up from 18% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
分析記事 • May 20HRS' (KOSDAQ:036640) Solid Earnings May Rest On Weak FoundationsHRS Co., Ltd's ( KOSDAQ:036640 ) healthy profit numbers didn't contain any surprises for investors. We think this is...
Reported Earnings • Mar 15Full year 2024 earnings released: EPS: ₩945 (vs ₩758 in FY 2023)Full year 2024 results: EPS: ₩945 (up from ₩758 in FY 2023). Revenue: ₩80.2b (up 2.6% from FY 2023). Net income: ₩15.1b (up 25% from FY 2023). Profit margin: 19% (up from 16% in FY 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 25HRS Co., Ltd, Annual General Meeting, Mar 26, 2025HRS Co., Ltd, Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 7, chupalsandan 2-gil, paengseong-eup, gyeonggi-do, pyeongtaek South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 09 April 2025. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 4.3%. Within top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (2.2%).
分析記事 • Dec 06We Like These Underlying Return On Capital Trends At HRS (KOSDAQ:036640)What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Declared Dividend • Nov 16Dividend of ₩200 announcedShareholders will receive a dividend of ₩200. Ex-date: 27th December 2024 Payment date: 9th April 2025 Dividend yield will be 6.2%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (40% cash payout ratio). The dividend has increased by an average of 46% per year over the past 5 years. However, payments have been volatile during that time. EPS is expected to grow by 8.8% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Nov 14Third quarter 2024 earnings released: EPS: ₩194 (vs ₩183 in 3Q 2023)Third quarter 2024 results: EPS: ₩194 (up from ₩183 in 3Q 2023). Revenue: ₩18.9b (down 4.7% from 3Q 2023). Net income: ₩3.10b (up 6.0% from 3Q 2023). Profit margin: 16% (up from 15% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 16% per year.
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩87.7b market cap, or US$66.7m).
Reported Earnings • May 18First quarter 2024 earnings released: EPS: ₩243 (vs ₩154 in 1Q 2023)First quarter 2024 results: EPS: ₩243 (up from ₩154 in 1Q 2023). Revenue: ₩20.5b (up 7.4% from 1Q 2023). Net income: ₩3.88b (up 58% from 1Q 2023). Profit margin: 19% (up from 13% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 12Full year 2023 earnings released: EPS: ₩758 (vs ₩628 in FY 2022)Full year 2023 results: EPS: ₩758 (up from ₩628 in FY 2022). Revenue: ₩78.2b (down 9.2% from FY 2022). Net income: ₩12.1b (up 21% from FY 2022). Profit margin: 16% (up from 12% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Dec 20Upcoming dividend of ₩200 per share at 3.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 3.7%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.8%).
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩183 (vs ₩121 in 3Q 2022)Third quarter 2023 results: EPS: ₩183 (up from ₩121 in 3Q 2022). Revenue: ₩19.8b (down 2.5% from 3Q 2022). Net income: ₩2.93b (up 51% from 3Q 2022). Profit margin: 15% (up from 9.5% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Apr 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩5,850, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 169% over the past three years.
Reported Earnings • Mar 12Full year 2022 earnings released: EPS: ₩628 (vs ₩1,303 in FY 2021)Full year 2022 results: EPS: ₩628 (down from ₩1,303 in FY 2021). Revenue: ₩86.1b (up 2.4% from FY 2021). Net income: ₩10.0b (down 52% from FY 2021). Profit margin: 12% (down from 25% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 42% per year whereas the company’s share price has increased by 44% per year.
Upcoming Dividend • Dec 21Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 3.5%. Within top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (2.4%).
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩6,240, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 151% over the past three years.
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩6,230, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 140% over the past three years.
Reported Earnings • Mar 11Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: ₩1,303 (up from ₩571 in FY 2020). Revenue: ₩84.1b (up 25% from FY 2020). Net income: ₩20.8b (up 126% from FY 2020). Profit margin: 25% (up from 14% in FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Over the next year, revenue is forecast to grow 19%, compared to a 22% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩7,530, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 152% over the past three years.
Upcoming Dividend • Dec 22Upcoming dividend of ₩150 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 13% but the company is not cash flow positive. Trailing yield: 2.1%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (1.5%).
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩6,660, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 137% over the past three years.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩191 (vs ₩164 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ₩21.0b (up 23% from 3Q 2020). Net income: ₩3.05b (up 16% from 3Q 2020). Profit margin: 14% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₩9,160, the stock trades at a trailing P/E ratio of 8.2x. Average trailing P/E is 20x in the Chemicals industry in South Korea. Total returns to shareholders of 213% over the past three years.
Valuation Update With 7 Day Price Move • Sep 06Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₩6,800, the stock trades at a trailing P/E ratio of 6.1x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 103% over the past three years.
Valuation Update With 7 Day Price Move • Jun 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩6,470, the stock trades at a trailing P/E ratio of 10.2x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 55% over the past three years.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩6,040, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 46% over the past three years.
分析記事 • Mar 16HRS Co., Ltd's (KOSDAQ:036640) 2.6% Dividend Yield Looks Pretty InterestingCould HRS Co., Ltd ( KOSDAQ:036640 ) be an attractive dividend share to own for the long haul? Investors are often...
Reported Earnings • Mar 10Full year 2020 earnings released: EPS ₩571 (vs ₩60.00 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩67.4b (up 1.0% from FY 2019). Net income: ₩9.21b (up ₩8.23b from FY 2019). Profit margin: 14% (up from 1.5% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 01Will HRS' (KOSDAQ:036640) Growth In ROCE Persist?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩5,810, the stock is trading at a trailing P/E ratio of 13.6x, down from the previous P/E ratio of 16.5x. This compares to an average P/E of 17x in the Chemicals industry in South Korea. Total returns to shareholders over the past three years are 30%.
Is New 90 Day High Low • Feb 15New 90-day high: ₩7,140The company is up 72% from its price of ₩4,145 on 17 November 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.
分析記事 • Feb 11A Look At The Intrinsic Value Of HRS Co., Ltd (KOSDAQ:036640)How far off is HRS Co., Ltd ( KOSDAQ:036640 ) from its intrinsic value? Using the most recent financial data, we'll...
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₩6,730, the stock is trading at a trailing P/E ratio of 15.7x, up from the previous P/E ratio of 12.6x. This compares to an average P/E of 18x in the Chemicals industry in South Korea. Total returns to shareholders over the past three years are 48%.
Is New 90 Day High Low • Jan 25New 90-day high: ₩5,750The company is up 67% from its price of ₩3,445 on 27 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 40% over the same period.
分析記事 • Jan 24HRS Co., Ltd (KOSDAQ:036640) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?HRS (KOSDAQ:036640) has had a great run on the share market with its stock up by a significant 58% over the last three...
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩5,500, the stock is trading at a trailing P/E ratio of 12.8x, up from the previous P/E ratio of 11.1x. This compares to an average P/E of 15x in the Chemicals industry in South Korea. Total returns to shareholders over the past three years are 31%.
Is New 90 Day High Low • Dec 29New 90-day high: ₩5,500The company is up 59% from its price of ₩3,470 on 29 September 2020. The South Korean market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period.
分析記事 • Dec 28Did You Miss HRS' (KOSDAQ:036640) 82% Share Price Gain?Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than...
Is New 90 Day High Low • Dec 10New 90-day high: ₩4,445The company is up 17% from its price of ₩3,800 on 11 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period.
分析記事 • Dec 02These 4 Measures Indicate That HRS (KOSDAQ:036640) Is Using Debt SafelyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Nov 18Third quarter 2020 earnings released: EPS ₩164The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ₩17.2b (up 1.1% from 3Q 2019). Net income: ₩2.63b (up 437% from 3Q 2019). Profit margin: 15% (up from 2.9% in 3Q 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Nov 09New 90-day high: ₩4,080The company is up 24% from its price of ₩3,300 on 11 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Oct 12New 90-day high: ₩3,970The company is up 16% from its price of ₩3,435 on 14 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 30% over the same period.